AUSTIN, Texas, Nov. 30, 2016 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (SCV) and AXIM® Biotechnologies, Inc. (AXIM®Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company’s Chief Executive Officer, George E. Anastassov, is featured in an audio interview at SmallCapVoice.com. The interview outlining the company’s business strategy and future is now available and can be heard at https://smallcapvoice.com/blog/11-29-16-smallcapvoice-interview-with-axim-biotechnologies-inc-axim.
George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech, called in to SmallCapVoice.com to discuss the company’s business model, target markets and exciting recent news. The Company recently announced that it filed an IP application with the World Intellectual Property Organization (WIPO) on a proprietary method to extract THC-A (tetrahydrocannabinol acid) from cannabis plants and to achieve THC (tetrahydrocannabinol) with higher purity than conventional methods.
George E. Anastassov commented, “Our unique opportunities in several new market segments were able to be detailed in this interview as well as our exciting plans for several upcoming projects. Our work to date has set the stage for an exciting end to 2016 and it was a pleasure discussing our achievements and progress with SmallCapVoice.com.”
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Stuart T. Smith
Public Relations Contact:
Chief Executive Officer
Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227